Long-term outcomes of add-on direct renin inhibition in IgA nephropathy: a propensity score-matched cohort study

Davina N. W. Lie, Kam Wa Chan, Alexander H. N. Tang, Anthony T. P. Chan, Gary C. W. Chan, Kar Neng Lai, Sydney Chi-Wai Tang*

*Corresponding author for this work

Research output: Contribution to journalJournal articlepeer-review

3 Citations (Scopus)


Introduction: The long-term clinical outcomes in biopsy proven IgAN patients treated with aliskiren on top of a maximally tolerated dose of ACEi/ARB remain unknown. Methods: Patients with IgAN treated with a direct renin inhibitor and ACEi/ARB for at least 6 months were compared with a 1:1 propensityscore-matched cohort (including MEST-C score and the 12-months pre-exposure slope of eGFR matching) who received ACEi/ARB without aliskiren exposure to compute the hazard ratio of reaching the primary endpoint of a composite of 40% reduction in eGFR, initiation of KRT and all-cause mortality. Secondary outcome measures included changes in mean UPCR, blood pressure, eGFR, incidence of hyperkalemia and other adverse events during follow-up. Results: After a median follow-up of 2.5 years, 8/36 (22.2%) aliskiren-treated patients and 6/36 (16.7%) control patients reached the primary composite outcome (HR = 1.60; 95% CI 0.52–4.88; P = 0.412). Aliskiren treatment increased the risk of ≥ 40% eGFR decline (HR = 1.60; 95% CI 0.52–4.88; P = 0.412), and hyperkalemia (HR = 8.60; 95% CI 0.99–73.64; P = 0.050). At 10.8 years, renal composite outcome was reached in 69.4% vs 58.3% (HR = 2.16; 95% CI 1.18–3.98; P = 0.013) of patients in the aliskiren and control groups, respectively. The mean UPCR reduction between treatment and control was not statistically different (52.7% vs 42.5%; 95% CI 0.63–2.35; P = 0.556). The mean intergroup difference in eGFR decline over 60 months was 7.75 ± 3.95 ml/min/1.73 m2 greater in the aliskiren group (12.83 vs 5.08; 95% CI − 0.17 to 15.66; P = 0.055). Conclusion: Among patients with IgAN, add-on aliskiren was associated with less favorable long-term kidney outcomes despite an initial anti-proteinuric effect. Graphic abstract: [Figure not available: see fulltext.].

Original languageEnglish
Pages (from-to)407-416
Number of pages10
JournalJournal of Nephrology
Issue number2
Early online date11 Jan 2023
Publication statusPublished - Mar 2023

Scopus Subject Areas

  • Medicine(all)
  • Nephrology
  • Epidemiology

User-Defined Keywords

  • Cohort study
  • IgA nephropathy
  • Renin-angiotensin system
  • Immunoglobulin A nephropathy
  • Aliskiren
  • Direct renin inhibitor
  • Chronic kidney disease


Dive into the research topics of 'Long-term outcomes of add-on direct renin inhibition in IgA nephropathy: a propensity score-matched cohort study'. Together they form a unique fingerprint.

Cite this